Pulmatrix, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
PULM Nasdaq 2830 www.pulmatrix.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Pulmatrix, Inc.

Eos SENOLYTIX Presents Late-Life Survival and Healthspan Data for Mitochondria-Targeted Geropeptide PTC-2105 at the 17th World Congress on Targeting Mitochondria, and Launches “Team Speedy” to Let the Public Follow Its Longest-Lived Mouse - Oct 22nd, 2026 6:00 am
Eos SENOLYTIX to Highlight Next-Generation Mitochondria-Targeted Therapeutics at 17th World Congress on Targeting Mitochondria - Sep 22nd, 2026 6:30 am
Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger - Aug 13th, 2026 6:15 am
Pulmatrix Announces First Quarter 2026 Financial Results - May 15th, 2026 6:20 am
Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger - Apr 21st, 2026 6:00 am
Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan - Mar 26th, 2026 6:00 am
Wave crashes on obesity drug update; Kodiak’s reboot pays dividends - Mar 26th, 2026 4:46 am
Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities - Mar 2nd, 2026 6:00 am
Pulmatrix and Cullgen Continue to Pursue Merger While Granting Each Other Waivers to Explore Alternatives - Dec 18th, 2025 6:05 am